ALT Hits New Low, FPRX Down 26% This Month, VBIV Prices Stock Offering

(RTTNews) - The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. Applied Genetic Technologies Corporation (AGTC)

Lost 47.10% to close Thursday's (Dec.13) trading at $3.47.

News: The Company announced disappointing topline interim six-month data from its phase I/II clinical trial of rAAV2tYF-CB-hRS1, an investigational AAV-based gene therapy, for X-linked retinoschisis due to mutations in the RS1 gene.

X-linked retinoschisis (XLRS) is a genetic condition affecting boys and men, and its main symptom is reduced vision that cannot be improved with glasses. (Source: NORD).

Although the results from the XLRS study support general safety and tolerability of AGTC's gene delivery platform, they do not demonstrate signs of clinical activity at interim six-month time point.

The Company has also terminated its collaboration with Biogen, which will become effective on March 8, 2019, and will regain full rights to the XLRS and X-linked retinitis pigmentosa (XLRP) programs and the three other partnered discovery programs.

2. LogicBio Therapeutics Inc. (LOGC)

LogicBio is a genome editing company focused on developing medicines for rare diseases.

Lost 21.77% to close Thursday's trading at $9.70.

News: No news

Recent events:

-- The Company went public on the Nasdaq Global Market on October 19, 2018, offering its shares at a price of $10 each.

Clinical Trials & Near-term Catalysts:

The Company expects to file an IND for LB-001 in late-2019 and initiate a Phase 1/2 trial in methylmalonic academia, an inborn error of metabolism, shortly thereafter.

3. Altimmune Inc. (ALT)

Lost 21.77% to close Thursday's trading at $9.70.

Pipeline:

Altimmune is a clinical-stage immunotherapeutics company having four clinical product candidates in its pipeline namely, NasoVAX, a phase II seasonal influenza vaccine candidate, HepTcell, a phase II-ready immunotherapeutic candidate for the potential cure of chronic hepatitis B, SPARVAX-L, a phase II Anthrax vaccine, and NasoShield, a next generation Anthrax vaccine, under phase I study.

Near-term Catalyst:

Results from Part B of phase I study of Anthrax vaccine NasoShield are expected in the first half of 2019.

4. Five Prime Therapeutics Inc. (FPRX)

Lost 18.59% to close Thursday's trading at $9.81.

News: No news

Pipeline & Near-term Catalysts:

-- A phase III global registrational trial of Bemarituzumab in gastric and gastroesophageal junction, dubbed FIGHT, is underway. -- A phase II clinical trial evaluating Cabiralizumab and Bristol-Myers Squibb Co.'s (BMS) OPDIVO in patients with advanced pancreatic cancer is ongoing. -- A Phase 1a/1b clinical trial of FPA150 in multiple cancers is underway.

5. VBI Vaccines Inc. (VBIV)

Lost 15.66% to close Thursday's trading at $1.40.

News: The Company has offered to sell 26.8 million shares of common stock to the public at a price of US$1.40 per share.

The underwriters have a 30-day option to purchase up to an additional 4.02 million common shares at US$1.40 per share. The offering, which is scheduled to close on or about December 17, 2018, is expected to rake in gross proceeds of about US$37.5 million.